Dual incretin-receptor pharmacology of the GLP-2 T analog
GLP-2 T is studied as a dual incretin-receptor agonist analog, with laboratory research centered on GLP-1R/GIPR structure and pathway-selective signaling.
Overview
Despite the VIVO shorthand, GLP-2 T is not the intestinal hormone GLP-2. It is presented as a dual incretin-receptor agonist analog corresponding to tirzepatide research. That distinction should be explicit on the page to avoid confusion with glucagon-like peptide-2 biology.
Structural studies have resolved tirzepatide in complexes with GLP-1 and GIP receptors and have examined how its amino-acid sequence and lipid modification shape binding. Cell-based assays further compare cAMP signaling, beta-arrestin recruitment, receptor internalization, and responses across receptor variants.
The literature supports receptor-structure, biased-signaling, and comparative pharmacology experiments. It does not mean a VIVO material was used in the cited work, and it does not establish safety, efficacy, dosing, administration, or an expected outcome in humans or animals.
References
Peer-reviewed sources for the research summarised above. Vivo summarises published, third-party science and does not conduct or sponsor this research.
- Sun B, Willard FS, Feng D, et al. (2022). Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences; 119(13):e2116506119. View source ↗
- Willard FS, Douros JD, Gabe MBN, et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight; 5(17):e140532. View source ↗
- Gasbjerg LS, et al. (2024). Tirzepatide, GIP(1–42), and GIP(1–30) display distinct signaling profiles at common GIP receptor variants. Frontiers in Endocrinology. View source ↗